Compass Therapeutics
Clinical trials sponsored by Compass Therapeutics, explained in plain language.
COMPASS Therapeutics is a biopharmaceutical company developing psychedelic-based therapies for mental health.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New experimental drug CTX-8371 enters first human tests for tough cancers Results expected Dec 2026 (estimated)
- New combo therapy shows promise for Tough-to-Treat bile duct cancer Results expected Aug 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
-
New hope for Tough-to-Treat colon cancer?
Disease control CompletedThis study tested an experimental drug called CTX-009 in 49 adults with metastatic colorectal cancer that had worsened after two or three prior treatments. The goal was to see if the drug could shrink tumors or stop them from growing. Results will help determine if further testin…
Phase 2 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New hope for cancer patients when immunotherapy fails?
Disease control CompletedThis early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…
Phase 1 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC